Plasmodium falciparum merozoite surface protein 2: Epitope mapping and fine specificity of human antibody response against non-polymorphic domains

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Balam, Saidou ^a,k   Olugbile, Sope ^b   Servis, Catherine ^a   Diakité, Mahamadou ^c   D'Alessandro, Alba ^d   Frank, Geraldine ^a   Moret, Remy ^e   Nebie, Issa ^f   Tanner, Marcel ^g   Felger, Ingrid ^g   Smith, Thomas ^g   Kajava, Andrey V ^h,i   Spertini, François ^j   Corradin, Giampietro ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b HOSPITAL OF SAINT RAPHAEL   (United States)

^c UNIVERSITY OF BAMAKO   (Mali)

^d UNIVERSITY OF SALERNO   (Italy)

^e Saint Camille Medical Centre (SCMC)   (Burkina Faso)

^f Burkina Faso   (Burkina Faso)

^g SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^h CNRS   (France)

ⁱ ITMO UNIVERSITY   (Russian Federation)

^j LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^k UNIVERSITY HOSPITAL REGENSBURG   (Germany)

more..

Author keywords

C terminal region; Dimorphic regions; Epitope mapping; Fine specificity; MSP2; Plasmodium falciparum

Indexed keywords

EPITOPE; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 2; SYNTHETIC PEPTIDE; MEROZOITE SURFACE PROTEIN 2, PLASMODIUM; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; BLOOD SAMPLING; CHILD; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; GROUPS BY AGE; HUMAN; IMMUNE RESPONSE; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; PLASMODIUM FALCIPARUM; PROTEIN PURIFICATION; SEQUENCE ALIGNMENT; WESTERN BLOTTING; BLOOD; CONSERVED SEQUENCE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; INFANT; MALE; MIDDLE AGED; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BLOTTING, WESTERN; CHILD; CHILD, PRESCHOOL; CONSERVED SEQUENCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INFANT; MALE; MIDDLE AGED; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; YOUNG ADULT;

EID: 84924126679     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-510     Document Type: Article

References (51)

1. World Health Organization: Malaria. http://www.who.int/topics/malaria/en/2011.
2. World Health Organization: World Malaria Report. ; 2011. http://www.who. int/malaria/world-malaria-report-2011/en/index.html 2011.
3. Flueck C, Smith T, Beck HP, Irion A, Betuela I, Alpers MP, Anders R, Saul A, Genton B, Felger I: Strain-specific humoral response to a polymorphic malaria vaccine. Infect Immun 2004, 72: 6300-6305.
4. Flueck C, Frank G, Smith T, Jafarshad A, Nebie I, Sirima SB, Olugbile S, Alonso P, Tanner M, Druilhe P, Felger I, Corradin G: Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates. Vaccine 2009, 27: 2653-2661.
5. Olugbile S, Kulangara C, Bang G, Bertholet S, Suzarte E, Villard V, Frank G, Audran R, Razaname A, Nebie I, Awobusuyi O, Spertini F, Kajava AV, Felger I, Druilhe P, Corradin G: Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage associated Plasmodium falciparum protein PFF0165c. Infect Immun 2009, 77: 5701-5709.
6. Theisen M, Dodoo D, Toure-Balde A, Soe S, Corradin G, Koram KK, Kurtzhals JA, Hviid L, Theander T, Akanmori B, Ndiaye M, Druilhe P: Selection of glutamate-rich protein long synthetic peptides for vaccine development: Antigenicity and relationship with clinical protection and immunogenicity. Infect Immun 2001, 69: 5223-5229.
7. Felger I, Tavul L, Kabintik S, Marshall V, Genton B, Alpers M, Beck HP: Plasmodium falciparum: Extensive polymorphism in merozoite surface antigen 2 alleles in an area with endemic malaria in Papua New Guinea. Exp Parasitol 1994, 79: 06-116.
8. Carvalho LJ, Daniel-Ribeiro CT, Goto H: Malaria vaccine: Candidate antigens, mechanism, constraints. Scand J Immunol 2002, 56: 327-343.
9. Cowman AF, Baldi DL, Healer J, Mills KE, O'Donnell RA, Reed MB: Functional analysis of proteins involved in Plasmodium falciparum merozoite invasion of red blood cells. FEBS Lett 2000, 476: 84-88.
10. Epping RJ, Goldstone SD, Ingram LT, Upcroft JA, Ramasamy R, Cooper JA: An epitope recognised by inhibitory monoclonal antibodies that react with a 51 kilodalton merozoite surface antigen in Plasmodium falciparum. Mol Biochem Parasitol 1988, 28: 1-10.
11. Ramasamy R, Jones G, Lord R: Characterisation of an inhibitory monoclonal antibody-defined epitope on a malaria vaccine candidate antigen. Immunol Lett 1990, 23: 305-309.
12. Taylor RR, Smith DB, Robinson VJ, McBride JS, Riley EM: Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass. Infect Immun 1995, 63: 4382-4388.
13. Metzger WG, Okenu DM, Cavanagh DR, Robinson JV, Bojang KA, Weiss HA, McBride JS, Greenwood BM, Conway DJ: Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria. Parasite Immunol 2003, 25: 307-312.
14. Stubbs J, Olugbile S, Saidou B, Simpore J, Corradin G, Lanzavecchia A: Strain-Transcending Fc-dependent killing of Plasmodium falciparum by merozoite surface protein 2 allele-specific human antibodies. Infect Immun 2011, 79: 1143-1152.
15. Anders RF, Smythe JA: Polymorphic antigens in Plasmodium falciparum. Blood 1989, 74: 1865-1875.
16. Felger I, Marshal VM, Reeder JC, Hunt JA, Mgone CS, Beck HP: Sequence diversity and molecular evolution of the merozoite surface antigen 2 of Plasmodium falciparum. J Mol Evol 1997, 45: 154-160.
17. Wright PE, Dyson JH: Intrinsically unstructured proteins: Re-Assessing the protein structure-function paradigm. J Mol Biol 1999, 293: 321-331.
18. Taylor RR, Allen SJ, Greenwood BM, Riley EM: IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): Increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg 1998, 58: 406-413.
19. Tebo AE, Kremsner PG, Luty AJ: Plasmodium falciparum: A major role for IgG3 in antibody-dependent monocyte-mediated cellular inhibition of parasite growth in vitro. Exp Parasitol 2001, 98: 20-28.
20. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P: Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 1995, 182: 409-418.
21. Genton B, Al-Yaman F, Anders R, Saul A, Brown G, Pye D, Irving DO, Briggs WR, Mai A, Ginny M, Adiguma T, Rare L, Giddy A, Reber-Liske R, Stuerchler D: Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine 2000, 18: 2504-2511.
22. Saul A, Lawrence G, Smillie A, Rzepczyk CM, Reed C, Taylor D, Anderson K, Stowers A, Kemp R, Allworth A, Anders RF, Brown GV, Pye D, Schoofs P, Irving DO, Dyer SL, Woodrow GC, Briggs WR, Reber R, Stürchler D: Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 1999, 17: 3145-3159.
23. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, Rare L, Baisor M, Lorry K, Brown GV, Pye D, Irving DO, Smith TA, Beck HP, Alpers MP: A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 2002, 185: 820-7.
24. Genton B, Al-Yaman F, Betuela I, Anders RF, Saul A, Baea K, Mellombo M, Taraika J, Brown GV, Pye D, Irving DO, Felger I, Beck HP, Smith TA, Alpers MP: Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine 2003, 22: 30-41.
25. McCarthy JS, Marjason J, Elliott S, Fahey P, Bang G, Malkin E, Tierney E, Aked-Hurditch H, Adda C, Cross N, Richards JS, Fowkes FJ, Boyle MJ, Long C, Druilhe P, Beeson JG, Anders RF: A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with montanide ISA 720. PLoS One 2011, 6: E2443.
26. Adda CG, Murphy VJ, Sunde M, Waddington LJ, Schloegel J, Talbo GH, Vingas K, Kienzle V, Masciantonio R, Howlett GJ, Hodder AN, Foley M, Anders RF: Plasmodium falciparum merozoite surface protein 2 is unstructured and forms amyloid-like fibrils. Mol Biochem Parasitol 2009, 166: 159-171.
27. Alonso PL, Smith T, Schellenberg JR, Masanja H, Mwankusye S, Urassa H, Bastos de Azevedo I, Chongela J, Kobero S, Menendez C: Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 1994, 344: 1175-1181.
28. Villard V, Agak GW, Frank G, Jafarshad A, Servis C, N?bi? I, Sirima SB, Felger I, Arevalo-Herrera M, Herrera S, Heitz F, Bdcker V, Druilhe P, Kajava AV, Corradin G: Rapid identification of malaria vaccine candidates based on a-helical coiled coil protein motif. PLoS One 2007, 2: E645.
29. Agak GW, Bejon P, Fegan G, Gicheru N, Villard V, Kajava AV, Marsh K, Corradin G: Longitudinal analyses of immune responses to Plasmodium falciparum derived peptides corresponding to novel blood stage antigens in coastal Kenya. Vaccine 2008, 26: 1963-1971.
30. Nozaki Y, Tanford C: Proteins as random coils. II. Hydrogen ion titration curve of ribonuclease in 6 M guanidine hydrochloride. J Am Chem Soc 1967, 89: 736-742.
31. Garcia-Mira MM, Sanchez-Ruiz JM: PH Corrections and Protein Ionization in Water/Guanidinium Chloride. Biophys J 2001, 81: 3489-3502.
32. Sanchez GI, Rogers WO, Mellouk S, Hoffman SL: Plasmodium falciparum: Exported protein-1, a blood stage antigen, is expressed in liver stage parasites. Exp Parasitol 1994, 79: 59-62.
33. Meraldi V, Nebié I, Tiono AB, Diallo D, Sanogo E, Theisen M, Druilhe P, Corradin G, Moret R, Sirima BS: Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection. Parasite Immunol 2004, 26: 265-272.
34. Bongfen SE, Ntsama PM, Offner S, Smith T, Felger I, Tanner M, Alonso P, Nebie I, Romero JF, Silvie O, Torgler R, Corradin G: The N-Terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity. Vaccine 2009, 27: 328-335.
35. Ferreira MU, Kimura EA, De Souza JM, Katzin AM: The isotype composition and avidity of naturally acquired anti-Plasmodium falciparum antibodies: Differential patterns in clinically immune Africans and Amazonian patients. Am J Trop Med Hyg 1996, 55: 315-23.
36. Leoratti FM, Durlacher RR, Lacerda MV, Alecrim MG, Ferreira AW, Sanchez MC, Moraes SL: Pattern of humoral immune response to Plasmodium falciparum blood stages in individuals presenting different clinical expressions of malaria. Malar J 2008, 7: 186.
37. Hedman K, Lappalainen M, Söderlund M, Hedman L: Avidity of IgG in serodiagnosis of infectious diseases. Rev Med Microbiol 1993, 4: 123-129.
38. Thomas HI, Wilson S, O'Toole CM, Lister CM, Saeed AM, Watkins RP, Morgan-Capner P: Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1. Clin Exp Immunol 1996, 103: 185-191.
39. Marcipar SI, Risso GM, Silber MA, Revelli S, Marcipar JA: Antibody maturation in Trypanosoma cruzi-infected rats. Clin Diagn Lab Immunol 2001, 8: 802-805.
40. Franks S, Baton L, Tetteh K, Tongren E, Dewin D, Akanmori BD, Koram KA, Ranford-Cartwright L, Riley EM: Genetic diversity and antigenic polymorphism in Plasmodium falciparum: Extensive serological cross-reactivity between allelic variants of merozoite surface protein 2. Infect Immun 2003, 71: 3485-3495.
41. Felger I, Steiger S, Hatz C, Smith T, Beck HP: Antigenic cross-reactivity between different alleles of the Plasmodium falciparum merozoite surface protein 2. Parasite Immunol 2003, 25: 531-543.
42. Falk N, Maire N, Sama W, Owusu-Agyei S, Smith T, Beck HP, Felger I: Comparison of PCR-RFLP and Genescan-based genotyping for analyzing infection dynamics of Plasmodium falciparum. Am J Trop Med Hyg 2006, 74: 944-950.
43. Henning L, Schellenberg D, Smith T, Henning D, Alonso P, Tanner M, Mshinda H, Beck HP, Felger I: A prospective study of Plasmodium falciparum multiplicity of infection and morbidity in Tanzanian children. Trans R Soc Trop Med Hyg 2004, 98: 687-694.
44. Lawrence N, Stowers A, Mann V, Taylor D, Saul A: Recombinant chimeric proteins generated from conserved regions of Plasmodium falciparum merozoite surface protein 2 generate antiparasite humoral responses in mice. Parasite Immunol 2000, 22: 211-221.
45. Thomas AW, Carr DA, Carter JM, Lyon JA: Sequence comparison of allelic forms of the Plasmodium falciparum merozoite surface antigen MSA2. Mol Biochem Parasitol 1990, 43: 211-220.
46. Stowers A, Taylor D, Prescott N, Cheng Q, Cooper J, Saul A: Assessment of the humoral immune response against Plasmodium falciparum rhoptry-Associated proteins 1 and 2. Infect Immun 1997, 65: 2329-2338.
47. Osier FH, Murungi LM, Fegan G, Tuju J, Tetteh KK, Bull PC, Conway DJ, Marsh K: Allele-specific antibodies to Plasmodium falciparum merozoite surface protein-2 and protection against clinical malaria. Parasite Immunol 2010, 32: 193-201.
48. Bouharoun-Tayoun H, Druilhe P: Plasmodium falciparum malaria: Evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect Immun 1992, 60: 1473-1481.
49. Fenton B, Clark JT, Khan CM, Robinson JV, Walliker D, Ridley R, Scaife JG, McBride JS: Structural and antigenic polymorphism of the 35-To 48-kilodalton merozoite surface antigen (MSA-2) of the malaria parasite Plasmodium falciparum. Mol Cell Biol 1991, 11: 963-971.
50. Saul A, Lord R, Jones G, Geysen HM, Gale J, Mollard R: Cross-reactivity of antibody against an epitope of the Plasmodium falciparum second merozoite surface antigen. Parasite Immunol 1989, 11: 593-601.
51. Plasmo DB: The Plasmodium genome resource. http://plasmodb.org 2014, Version 12.0.